i-HDS feasibility in 92 evaluable patients (100%)
| Toxic deaths | 2 (2%) |
| Treatment withdrawals | 3 (3%) |
| Not given transplants | 4 (4%) |
| Low mobilization | 3 (3%) |
| Toxicity | 1 (1%) |
| Progressions | 3 (3%) |
| Patients successfully given transplants | 80 (87%) |
| Median CD34+ cells × 106/kg mobilized (range) | 10.4 (0.6-81.6) |
| Toxic deaths | 2 (2%) |
| Treatment withdrawals | 3 (3%) |
| Not given transplants | 4 (4%) |
| Low mobilization | 3 (3%) |
| Toxicity | 1 (1%) |
| Progressions | 3 (3%) |
| Patients successfully given transplants | 80 (87%) |
| Median CD34+ cells × 106/kg mobilized (range) | 10.4 (0.6-81.6) |